ArticleFrontiers in cardiovascular medicine2025
The effect of different treatment strategies on the right heart dysfunction during follow-up in the patients with acute pulmonary thromboembolism of intermediate-risk.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Mechanical Thrombectomy Versus Anticoagulation in Intermediate-Risk Pulmonary Embolism: A Systematic Review and Meta-Analysis.Cardiovascular and interventional radiology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute pulmonary embolism (APE) is a disease with a high incidence and mortality rate. Currently, the preferred treatment methods for low - risk and high - risk of APE have been clearly defined, but there is still controversy regarding the optimal treatment for the intermediate - risk of APE. Patients with intermediate-risk APE have a relatively high thrombus burden, which can cause right heart function impairment during the follow-up period. It is still uncertain whether reperfusion therapy has an impact on right heart function during the follow-up period. Objectives: This study aims to evaluate the impact of reperfusion therapy on right heart function during the follow-up period in intermediate-risk APE patients by comparing the effects of different treatment strategies on right heart dysfunction (RHD) at 3 months. Methods: This study retrospectively included 216 patients who met the inclusion and exclusion criteria of this study. According to the treatment methods used, the patients were divided into the thrombolysis group, the catheter-directed thrombectomy group and the anticoagulation group. Results: In this study, the median follow - up time was 4.2 (3.1, 5.4) months. Among the patients with intermediate-risk APE, the incidence of RHD in the catheter-directed thrombectomy group was lower than that in the anticoagulation group ( Conclusion: In patients with intermediate-risk APE, reperfusion therapy may reduce the occurrence of RHD impairment events after 3 months and improve the prognosis of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.